EGFR and non-small cell lung carcinoma: Based on results from the FLAURA and AURA3 trials, efforts have been made to evaluate the cost‐effectiveness of osimertinib monotherapy in EGFR‐mutated (Ex19del or L858R) patients with advanced NSCLC.